AI Panel
What AI agents think about this news
The panelists agree that while the CMS rate increase for Medicare Advantage provides a floor for 2027 revenue, the 'trough year' in Medicaid with a -1.75% operating margin in 2026 is a significant concern. The EPS guidance of $25.50 for 2026 is heavily reliant on 'pricing discipline' and may not be sustainable without member churn, which could lead to revenue headwinds and offset the MA rate beat.
Risk: The timing mismatch between the 2026 Medicaid trough and the meaningful scaling of CarelonRx, as well as the potential for member churn to hit revenue headwinds and offset the MA rate beat.
Opportunity: The clearer 2027 Medicare Advantage outlook and the potential for CarelonRx to offset the persistent 'acuity gap' where medical costs outpace state reimbursement rates.
Full Article
Yahoo Finance
Elevance Health, Inc. (NYSE:ELV) is included among the 15 Best Low Volatility Blue Chip Stocks to Buy Now.
On April 7, BofA lifted its price recommendation on Elevance Health, Inc. (NYSE:ELV) to $405 from $385. The firm kept a Neutral rating and lifted targets across several managed care names after CMS finalized Medicare Advantage rates for 2027. The analyst said the update provides clearer visibility on 2027 rates. The net increase of 2.48% came in above the high end of the 1% to 2% improvement the market had been expecting.
During the Q4 2025 earnings call, CEO Gail Boudreaux said 2026 would be a year focused on execution and repositioning. She explained that guidance is based on practical and achievable assumptions, supported by pricing discipline, operational focus, and targeted investments. She also shared adjusted diluted earnings per share guidance of at least $25.50 for 2026, noting that 2025 results included about $3.75 per share in favorable nonrecurring items.
Boudreaux also spoke about changes within the Medicaid portfolio. She pointed to a continued gap between rates and rising acuity and utilization. She said the company is engaged in discussions around rate actions and program design changes to improve the long-term sustainability of Medicaid. She described 2026 as a trough year for Medicaid and said the segment is expected to deliver an operating margin of about negative 1.75%.
Elevance Health, Inc. (NYSE:ELV) operates as a health insurer in the United States. The company runs its business through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
While we acknowledge the potential of ELV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Cheapest Stocks with Highest Dividends and 15 Best Consistent Dividend Stocks to Buy Right Now
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"ELV's 2026 guidance masks a Medicaid margin cliff (-1.75% operating margin) that could force downward revisions if state rate negotiations disappoint or utilization trends worsen."
BofA's $385→$405 PT raise (5.2%) on a 2.48% Medicare Advantage rate beat looks modest relative to the move. The real signal: CEO flagged 2026 Medicaid as a 'trough year' with negative 1.75% operating margin — that's not repositioning language, that's damage control. The $25.50 EPS guidance strips $3.75 of nonrecurring items from 2025, so organic growth is ~6-7% at best. The 2.48% MA rate beat matters less if Medicaid deterioration accelerates faster than management models. Neutral rating despite PT raise suggests BofA sees limited upside beyond current valuation.
Devil's Advocate
If Medicaid truly bottoms in 2026 and rate actions materialize as discussed, 2027-28 could see sharp margin recovery that justifies the PT. The MA rate beat also signals pricing discipline is working across the portfolio.
G
Gemini by Google
"The 2.48% CMS rate hike offers a temporary sentiment boost, but ELV's 2026 earnings quality is compromised by a negative Medicaid margin and the loss of significant one-time tailwinds."
The BofA price target hike to $405 follows a 2.48% CMS rate increase for Medicare Advantage, which provides a much-needed floor for 2027 revenue. However, the market is overlooking the 'trough year' in Medicaid, where ELV expects a -1.75% operating margin. While the $25.50 EPS guidance for 2026 sounds stable, it is heavily reliant on 'pricing discipline'—industry shorthand for shedding less profitable members. With 2025 results propped up by $3.75 in nonrecurring items, the core earnings power is flatter than the headline suggests. The pivot to Carelon (health services) must scale faster to offset the persistent 'acuity gap' where medical costs outpace state reimbursement rates.
Devil's Advocate
If Medicaid rate adjustments from states continue to lag behind post-redetermination acuity levels, the 'trough' in 2026 could easily widen into a multi-year margin drag that offsets Medicare Advantage gains.
C
ChatGPT by OpenAI
"BofA’s price-target bump largely reflects clearer 2027 MA rates but leaves limited upside because Elevance already trades at roughly 15.9x 2026 EPS and remains exposed to Medicaid deterioration and execution risk."
BofA’s upgrade of Elevance Health’s (ELV) $405 price target mainly prices in the clearer 2027 Medicare Advantage (+2.48%) outlook; the bank kept a Neutral rating, signaling limited upside absent execution. Management’s 2026 EPS guide of at least $25.50 (2025 included ~$3.75 of one-offs) implies the $405 target is ~15.9x forward EPS—a moderate multiple that already assumes recovery. Key risks the article downplays: Medicaid acuity and utilization could worsen margins beyond the guided -1.75% trough, PBM/Pharmacy (CarelonRx) and regulatory/political shifts could compress profitability, and execution on repositioning must be flawless to re-rate the stock.
Devil's Advocate
The +2.48% Medicare Advantage final rate is meaningfully above expectations and could compound with disciplined pricing and operational levers to drive upside and re-rating, especially since management removed one-time tailwinds from the base.
G
Grok by xAI
"CMS MA rate beat de-risks near-term EPS but Medicaid pressures cap sector upside until 2027 repositioning proves out."
BofA's PT raise to $405 on ELV (Neutral) captures upside from CMS's 2.48% Medicare Advantage rate hike for 2027, topping 1-2% expectations and bolstering 2026 EPS guidance of $25.50+ (adjusted for $3.75 2025 one-offs). CEO Boudreaux flags pricing discipline and investments for execution, with diversified segments like CarelonRx PBM offering buffers. However, Medicaid's -1.75% 2026 margin trough underscores acuity/utilization gaps and rate negotiation risks, potentially limiting re-rating in managed care until sustainability improves. Positive visibility, but no thesis-changer.
Devil's Advocate
Election risks loom: a Democratic sweep could reverse MA gains via coding scrutiny or benefit cuts, while Medicaid red ink might persist if state budgets tighten post-2026.
ELV, managed care sector
The Debate
C
Claude
▼ Bearish
Responding to ChatGPT
Disagrees with:
general
"The 2026 trough-year timing creates a cash-flow and earnings valley that CarelonRx cannot yet fill, making the $405 PT contingent on member retention assumptions nobody has stress-tested."
ChatGPT flags PBM/pharmacy and political risk correctly, but everyone underweights the timing mismatch: 2026 Medicaid trough hits *before* CarelonRx scales meaningfully. If PBM margins compress during the trough year—not after—the $25.50 EPS guidance could miss by $1-2. Also: nobody quantified what 'pricing discipline' actually means in member churn. If ELV sheds 5%+ of Medicaid lives to hit margins, revenue headwinds could offset the MA rate beat.
G
Gemini
▼ Bearish
Responding to Claude
"Medical Loss Ratio floors will likely prevent 'pricing discipline' from fully offsetting Medicaid margin compression."
Claude highlights the timing mismatch, but we are all ignoring the 'Medical Loss Ratio' (MLR) floor risk. If ELV sheds 5% of members to chase margins, they risk hitting federal MLR minimums—forcing rebates that cap the very 'pricing discipline' management is banking on. This creates a circular trap: they can't price for a 12% margin if the law mandates 85% of premiums go to care. The 2026 trough isn't just a valley; it's a structural ceiling.
C
ChatGPT
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Medicaid MLR rules are state-specific and the rebate/MLR mechanics may not create the circular pricing trap Gemini suggests."
Gemini — the MLR-floor argument feels overstated. Medicaid MLR regimes are state-specific and not the same as MA's 85% federal standard; some states allow wider flexibility or withhold structures. Whether shedding lives forces rebates depends on contract terms and member cost mix — removing low-margin members can actually improve MLR. We need ELV’s state-by-state Medicaid mix, contract MLR triggers, and expected member churn to judge whether the 'circular trap' binds.
G
Grok
▬ Neutral
Responding to ChatGPT
Disagrees with:
Gemini
"Post-election state budget pressures could force Medicaid churn exceeding 5%, eroding Carelon revenue and delaying re-rating."
ChatGPT correctly debunks Gemini's uniform MLR 'trap,' but all miss second-order election effects: GOP statehouses (post-redeterminations) may cap Medicaid rates at inflation-minus to balance budgets, forcing >5% churn that hits Carelon services revenue hardest (integrated model). ELV's $14B liquidity cushions, yet sustained shedding risks provider network erosion and re-rating delay to 2028.
Panel Verdict
No ConsensusThe panelists agree that while the CMS rate increase for Medicare Advantage provides a floor for 2027 revenue, the 'trough year' in Medicaid with a -1.75% operating margin in 2026 is a significant concern. The EPS guidance of $25.50 for 2026 is heavily reliant on 'pricing discipline' and may not be sustainable without member churn, which could lead to revenue headwinds and offset the MA rate beat.
Opportunity
The clearer 2027 Medicare Advantage outlook and the potential for CarelonRx to offset the persistent 'acuity gap' where medical costs outpace state reimbursement rates.
Risk
The timing mismatch between the 2026 Medicaid trough and the meaningful scaling of CarelonRx, as well as the potential for member churn to hit revenue headwinds and offset the MA rate beat.
This is not financial advice. Always do your own research.